BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1710744)

  • 1. Effects of various lipid-lowering treatments in diabetics.
    Steiner G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S35-9. PubMed ID: 1710744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherosclerotic risk factors in cardiovascular disease.
    LaRosa JC
    J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women, lipoproteins and cardiovascular disease risk.
    LaRosa JC
    Can J Cardiol; 1990 May; 6 Suppl B():23B-29B. PubMed ID: 2188715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
    McKenney JM
    Pharmacotherapy; 1993; 13(4):340-52. PubMed ID: 8361860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal particle size of lipoprotein in non-insulin-dependent diabetics and nondiabetics with and without hyperlipidemia.
    Nakajo Y; Tanaka A; Uchimura I
    Bull Tokyo Med Dent Univ; 1991 Dec; 38(4):63-71. PubMed ID: 1764762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.